DaVita Inc. (DVA)

Market Cap	9.65B -30.1%
Revenue (ttm)	13.64B +6.5%
Net Income	746.80M -20.2%
EPS	9.84 -8.3%
Shares Out	68.55M
PE Ratio	14.81
Forward PE	9.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,255,174
Open	149.00
Previous Close	149.22
Day's Range	139.54 - 151.42
52-Week Range	101.00 - 178.38
Beta	1.01
Analysts	Hold
Price Target	156.75 (+11.3%)
Earnings Date	Feb 2, 2026

About DVA

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition...

• Industry: Medical Care Facilities
• Sector: Healthcare
• IPO Date: Oct 31, 1995
• Employees: 76,000
• Stock Exchange: NYSE
• Ticker Symbol: DVA
• Website: https://www.davita.com

Financial Performance

In 2025, DaVita's revenue was $13.64 billion, an increase of 6.46% compared to the previous year's $12.82 billion. Earnings were $746.80 million, a decrease of -20.24%.

Analyst Summary

According to 4 analysts, the average rating for DVA stock is "Hold." The 12-month stock price target is $156.75, which is an increase of 11.30% from the latest price.

Price Target

$156.75

(11.30% upside)

Analyst Consensus: Hold